Driehaus Capital Management LLC Has $95.82 Million Holdings in Glaukos Corporation $GKOS

Key Points

• Driehaus Capital Management LLC increased its stake in Glaukos Corporation by 18.7%, now holding approximately $95.82 million worth of stock, which accounts for 0.9% of its portfolio.
• Several analysts have downgraded their price targets for Glaukos, with Needham & Company lowering theirs from $176.00 to $115.00, while maintaining a "buy" rating.
• Glaukos reported a 29.7% increase in revenue year-over-year, totaling $124.12 million for the last quarter, surpassing analyst expectations.

Driehaus Capital Management LLC increased its position in Glaukos Corporation (NYSE:GKOS - Free Report) by 18.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 973,625 shares of the medical instruments supplier's stock after purchasing an additional 153,502 shares during the period. Glaukos makes up 0.9% of Driehaus Capital Management LLC's investment portfolio, making the stock its 17th largest holding. Driehaus Capital Management LLC owned about 1.70% of Glaukos worth $95,824,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of GKOS. Bessemer Group Inc. boosted its holdings in Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 158 shares in the last quarter. Whipplewood Advisors LLC grew its stake in Glaukos by 3,957.1% during the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 277 shares during the last quarter. First Horizon Advisors Inc. boosted its position in Glaukos by 72.9% during the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock worth $37,000 after purchasing an additional 159 shares in the last quarter. Versant Capital Management Inc grew its position in Glaukos by 583.9% in the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock worth $38,000 after acquiring an additional 327 shares during the period. Finally, CoreCap Advisors LLC raised its stake in shares of Glaukos by 36.4% in the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 99.04% of the company's stock.

Glaukos Stock Down 1.9%

GKOS stock traded down $1.79 during trading on Tuesday, reaching $94.03. 467,073 shares of the company traded hands, compared to its average volume of 936,905. The company has a market capitalization of $5.39 billion, a price-to-earnings ratio of -56.99 and a beta of 0.77. Glaukos Corporation has a 12 month low of $77.10 and a 12 month high of $163.71. The business has a 50 day simple moving average of $95.60 and a 200 day simple moving average of $98.45. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02. The company had revenue of $124.12 million for the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.Glaukos's revenue was up 29.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on GKOS. Wells Fargo & Company lifted their target price on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Zacks Research downgraded shares of Glaukos from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. BTIG Research reiterated a "buy" rating on shares of Glaukos in a research report on Monday, July 14th. William Blair raised shares of Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Finally, UBS Group lifted their price target on shares of Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $127.42.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.